cihr_grants: 170526
This data as json
| external_id | title | project_lead_name | co_researchers | institution | province | country | competition_year | award_amount | program | program_type | theme | research_subject | keywords | abstract | duration | source_url |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 170526 | Metabolic Regulation of Toll-like Receptor Agonist Therapy in Leukemia | Spaner David E | Spaner, David E | Sunnybrook Research Institute (Toronto, Ontario) | Ontario | Canada | 200809 | 380709.0 | Operating Grant | Operating Grants | Biomedical | Cancer Research | Apoptosis; Cancer; Cytokines; Flow Cytometry; Glucose; Mitochondria | Chemotherapy does not cure most cancers. However, the results with chemotherapy may be improved with treatments that increase the ability of the immune system to kill cancer cells (or immunotherapy). We have found that a new agent (called S28690), which activates a receptor on immune cells, called Toll-like receptor 7 (or TLR7), makes tumor cells more susceptible to both chemotherapy in the test tube but is not as effective in patients. The proposed research will determine how to make S28690 more effective in patients with Chronic Lymphocytic Leukemia, which is a tumor of the blood system. If these studies are successful,a new treatment for leukemia, and possibly other cancers, will become available. | 3 yrs 0 mth | https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=170526&lang=en |